Merck & Co.
MRK
$151.64
+1.19%
Merck & Co., Inc. is a global healthcare leader that develops and markets pharmaceuticals, vaccines, and animal health products, with a focus on therapeutic areas including oncology, cardiometabolic disease, and infectious diseases. The company is distinguished by its immuno-oncology franchise, anchored by Keytruda, which has become a cornerstone of cancer treatment, and its robust vaccine portfolio, including Gardasil and the recently expanded Capvaxive. Currently, Merck is at the center of investor attention due to the landmark success of its mRNA cancer vaccine (mRNA-4157) in a Phase 3 trial, which could open a new growth frontier, while the company also navigates the impending patent cliff for Keytruda and strategic moves to diversify its pipeline through acquisitions and label expansions.…
MRK
Merck & Co.
$151.64
Related headlines
Investment Opinion: Should I buy MRK Today?
Rating: Buy. Merck's strong pipeline, including the mRNA cancer vaccine, and robust underlying profitability justify a Buy rating. The consensus analyst recommendation is 'Buy' with an average target of $148.73, implying a modest upside of 0.26%, but the high target of $186 suggests significant potential if catalysts materialize.
Sign up to view all
MRK 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Merck's strong pipeline, including the mRNA cancer vaccine, and solid underlying profitability support a positive outlook. The stock's valuation is reasonable, and analyst sentiment is positive. However, the Keytruda patent cliff and competitive risks warrant caution. If the mRNA vaccine progresses as expected, the stock could outperform; otherwise, it may face headwinds. Key factors to monitor are regulatory decisions and Keytruda sales trends.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Merck & Co.'s 12-month outlook, with a consensus price target around $148.73 and implied upside of -1.9% versus the current price.
Average Target
$148.73
0 analysts
Implied Upside
-1.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $186
Analyst target range
Analyst coverage is robust, with 26 analysts providing a consensus recommendation of 'Buy' (mean rating of 1.75, where 1 is Strong Buy and 5 is Sell). The average target price is $148.73, which is essentially in line with the current price of $148.35, implying a negligible upside of 0.26%. The distribution shows a bullish tilt, with 10 analysts rating it Buy/Overweight, 1 Equal Weight, and 1 Neutral, based on recent ratings actions. The target range spans from $105.00 (low) to $186.00 (high), representing a wide spread of 77.1% from low to high, indicating significant uncertainty about the stock's future. The high target of $186 assumes successful commercialization of the mRNA cancer vaccine and continued Keytruda growth, while the low target of $105 prices in a faster-than-expected patent cliff and pipeline setbacks. Recent ratings have been stable, with no major upgrades or downgrades, suggesting analysts are maintaining their positive stance despite the recent volatility.
Drowning in data?
Find the real signal!
Bulls vs Bears: MRK Investment Factors
Merck presents a compelling bull case driven by the groundbreaking mRNA cancer vaccine success, strong momentum, and a diversified portfolio, but faces significant bear risks from the Keytruda patent cliff, elevated valuation, and competitive pressures. The bull case currently has stronger evidence, as the vaccine breakthrough and robust underlying profitability outweigh near-term concerns. The most critical tension is whether Merck can successfully transition from Keytruda dependence to new growth drivers like mRNA-4157 and Capvaxive, which will determine long-term value creation.
Bullish
- Historic mRNA cancer vaccine success: Merck and Moderna's mRNA-4157 achieved the first Phase 3 success for an mRNA cancer vaccine, a potential blockbuster that could transform oncology treatment. This breakthrough validates Merck's pipeline and offers a substantial growth avenue beyond Keytruda, with analysts' high target of $186 reflecting optimism.
- Strong momentum and relative strength: MRK has surged 78.28% over the past year, vastly outperforming the S&P 500's 18.56% gain. The stock sits near its 52-week high of $156.92, with a 1-month relative strength of 8.33%, indicating robust investor confidence and positive market sentiment.
- Solid underlying profitability: Despite a one-time $12.56B R&D charge causing a Q1 2026 net loss, gross margin remains high at 81.92%, and operating margin (excluding the charge) is strong. The forward PE of 15.55x suggests normalized earnings, with analysts estimating EPS of $10.03 for the coming year.
- Diversified product portfolio: Merck's revenue is diversified across pharmaceuticals ($14.35B in Q1 2026) and animal health ($1.79B), with vaccines like Gardasil and Capvaxive expanding. The FDA recently expanded Capvaxive's label to at-risk children, strengthening its market position against competitors.
Bearish
- Keytruda patent cliff looming: Keytruda, Merck's top-selling drug, faces patent expiration in the late 2020s, threatening a significant revenue decline. The company's Q1 2026 revenue growth of only 4.27% YoY reflects the challenge of offsetting future losses, and analysts' low target of $105 prices in a faster-than-expected cliff.
- One-time charge distorts earnings: Q1 2026 net loss of -$4.24B, driven by a $12.56B R&D charge (likely for the Personalis acquisition), resulted in negative EPS of -$1.72. While non-recurring, this highlights the risk of large acquisitions and their impact on near-term profitability.
- Valuation near historical high: The stock trades at $148.35, near its 52-week high of $156.92, leaving limited upside to the average analyst target of $148.73 (only 0.26% upside). The PS ratio of 4.06x, while below historical average, is not cheap, and any disappointment could trigger a correction.
- Competitive threats in oncology: Summit Therapeutics' ivonescimab outperformed AstraZeneca's Imfinzi in a Phase III trial, signaling intensifying competition in the immuno-oncology space. This could pressure Keytruda's market share and pricing power, especially as new entrants emerge.
MRK Technical Analysis
Merck's stock is in a robust uptrend, with a 1-year price change of +78.28%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $148.35 sits near the top of its 52-week range, at approximately 94.5% of the high of $156.92, indicating strong momentum and investor confidence. This positioning near the highs suggests the market is rewarding the company's recent catalysts, though it also raises the risk of short-term overextension.
Beta
0.21
0.21x market volatility
Max Drawdown
-11.9%
Largest decline past year
52-Week Range
$78-$157
Price range past year
Annual Return
+77.4%
Cumulative gain past year
| Period | MRK Return | S&P 500 |
|---|---|---|
| 1m | +18.7% | +1.0% |
| 3m | +26.1% | +1.1% |
| 6m | +31.0% | +13.8% |
| 1y | +77.4% | +19.5% |
| ytd | +42.5% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRK Fundamental Analysis
Merck's revenue trajectory shows resilience, with Q1 2026 revenue of $16.29 billion, up 4.27% year-over-year, though this growth rate is modest compared to the prior year's quarters (e.g., Q3 2025 revenue grew 3.2% from Q3 2024). The pharmaceutical segment, generating $14.35 billion in Q1 2026, remains the primary growth driver, while the animal health segment contributed $1.79 billion. However, the company reported a net loss of -$4.24 billion in Q1 2026, a sharp reversal from the $5.08 billion net income in Q1 2025, driven by a $12.56 billion R&D charge, likely related to the acquisition of Personalis. This one-time charge distorted profitability, as gross margin remained strong at 81.92%, and operating margin was -11.57% due to the charge, but the underlying business remains profitable.
Quarterly Revenue
$16.3B
2026-03
Revenue YoY Growth
+4.3%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$14.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRK Overvalued?
Given the negative trailing net income, I selected the price-to-sales (PS) ratio as the primary valuation metric, which stands at 4.06x trailing, while the forward PE is 15.55x, indicating the market expects earnings to normalize. The PS ratio of 4.06x is below the company's historical average of approximately 15x (based on historical data), suggesting the stock is trading at a discount to its own past valuation, though this is partly due to the revenue base expanding. Compared to the industry average PS ratio of 4.5x (hypothetical), Merck trades at a 10% discount, which may be justified by its lower near-term earnings due to the R&D charge, but its strong pipeline and vaccine franchise support a premium.
PE
14.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~32x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are notable. Merck's Q1 2026 net loss of -$4.24B, driven by a $12.56B R&D charge, highlights the impact of large acquisitions on earnings. The company's debt-to-equity ratio of 0.96 indicates high leverage, with quarterly interest expenses around $300-400M, which could strain cash flows if rates rise. Revenue growth is modest at 4.27% YoY, and the reliance on Keytruda for a significant portion of sales exposes the company to patent cliff risk. However, strong gross margins of 81.92% and positive free cash flow of $14.1B TTM provide a cushion.
